Europe Biologics Market to 2031 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Biologics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Biologics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Preference for Outsourcing Manufacturing Operations

5.2 Market Opportunities

5.2.1 Gene and Cell Therapy Advancements in Biologics

5.3 Future Trends

5.3.1 Strategic Initiatives by Companies

5.4 Impact of Drivers and Restraints

6. Europe Biologics Market Regional Analysis

6.1 Europe Biologics Market Overview

6.2 Europe Biologics Market Revenue 2025-2023 (US$ Million)

6.3 Europe Biologics Market Forecast Analysis

7. Europe Biologics Market Analysis – by Product

7.1 Monoclonal Antibodies

7.1.1 Overview
7.1.2 Monoclonal Antibodies: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Vaccine

7.2.1 Overview
7.2.2 Vaccine: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Recombinant Hormones/Proteins

7.3.1 Overview
7.3.2 Recombinant Hormones/Proteins: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Cell and Gene Therapy

7.4.1 Overview
7.4.2 Cell and Gene Therapy: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Others

7.5.1 Overview
7.5.2 Others: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Biologics Market Analysis – by Application

8.1 Cancer

8.1.1 Overview
8.1.2 Cancer: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview
8.2.2 Infectious Diseases: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

8.3 Autoimmune Diseases

8.3.1 Overview
8.3.2 Autoimmune Diseases: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

8.4 Others

8.4.1 Overview
8.4.2 Others: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

9. Europe Biologics Market Analysis – by Source

9.1 Mammalian and Microbial

9.1.1 Overview
9.1.2 Others: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10. Europe Biologics Market – Europe Analysis

10.1 Europe

10.1.1 Europe Biologics Market Breakdown, by Key Country, 2021 and 2023 (%)
10.1.1.1 Europe Biologics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 Germany: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.1.1 Germany: Europe Biologics Market Breakdown, by Product
10.1.1.1.2 Germany: Europe Biologics Market Breakdown, by Application
10.1.1.1.3 Germany: Europe Biologics Market Breakdown, by Source

10.1.1.2 the UK: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.2.1 the UK: Europe Biologics Market Breakdown, by Product
10.1.1.2.2 the UK: Europe Biologics Market Breakdown, by Application
10.1.1.2.3 the UK: Europe Biologics Market Breakdown, by Source

10.1.1.3 France: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.3.1 France: Europe Biologics Market Breakdown, by Product
10.1.1.3.2 France: Europe Biologics Market Breakdown, by Application
10.1.1.3.3 France: Europe Biologics Market Breakdown, by Source

10.1.1.4 Italy: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.4.1 Italy: Europe Biologics Market Breakdown, by Product
10.1.1.4.2 Italy: Europe Biologics Market Breakdown, by Application
10.1.1.4.3 Italy: Europe Biologics Market Breakdown, by Source

10.1.1.5 Spain: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.5.1 Spain: Europe Biologics Market Breakdown, by Product
10.1.1.5.2 Spain: Europe Biologics Market Breakdown, by Application
10.1.1.5.3 Spain: Europe Biologics Market Breakdown, by Source

10.1.1.6 Rest of Europe: Europe Biologics Market – Revenue and Forecast to 2023 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Biologics Market Breakdown, by Product
10.1.1.6.2 Rest of Europe: Europe Biologics Market Breakdown, by Application
10.1.1.6.3 Rest of Europe: Europe Biologics Market Breakdown, by Source

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Biologics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Samsung Biologics Co Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 ADMA Biologics, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Wuxi Biologics Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Catalent Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 AGC Biologics AS

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 AstraZeneca Plc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Amgen Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Nitto Avecia

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

13.11 Quality Assistance s.a.

13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments

14. Appendix

14.1 About Business Market Insights